SCHEMBL2910700

SCHEMBL2910700

CC1(c2cc([N+](=O)[O-])ccc2OC(=O)Oc2ccc([N+](=O)[O-])cc2C2(C)CCOC2)CCOC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
BACE1 P56817 2/20 0.42
BACE2 Q9Y5Z0 2/20 0.42
KMT2A Q03164 6/20 0.40
HTT P42858 6/20 0.39
MEN1 O00255 4/20 0.39
PKM P14618 2/20 0.39
MAPK1 P28482 1/20 0.39
PAX8 Q06710 1/20 0.39
LMNA P02545 5/20 0.38
ALDH1A1 P00352 3/20 0.38
RAB9A P51151 3/20 0.38
AKR1B1 P15121 1/20 0.37
MITF O75030 1/20 0.37
MAPT P10636 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
NFKB1 P19838 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910705 0.93 SMN1; SMN2 (0.48) SMN1; SMN2BACE1BACE2KMT2AHTT
SCHEMBL2910703 0.93 SMN1; SMN2 (0.48) SMN1; SMN2BACE1BACE2KMT2AHTT
SCHEMBL31441615 0.82 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AHTTMEN1PKM
SCHEMBL4332383 0.79 BACE2 (0.44) SMN1; SMN2BACE1BACE2HTTLMNA
SCHEMBL9938244 0.79 ALDH1A1 (0.42) SMN1; SMN2KMT2AHTTMEN1PKM
SCHEMBL9938240 0.79 ALDH1A1 (0.42) SMN1; SMN2KMT2AHTTMEN1PKM
SCHEMBL3135662 0.70 ALDH1A1 (0.56) KMT2AHTTMEN1PKMALDH1A1
SCHEMBL29379815 0.69 ALDH1A1 (0.55) SMN1; SMN2KMT2AMEN1MAPK1LMNA
SCHEMBL1220299 0.69 ALDH1A1 (0.55) SMN1; SMN2KMT2AMEN1MAPK1LMNA
SCHEMBL5492543 0.68 ALDH1A1 (0.46) SMN1; SMN2KMT2AHTTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637528-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2010-09-01 EP disclosed
EP-1637528-A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-03-22 EP disclosed
EP-1136479-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2005-12-28 EP disclosed
EP-0833826-B1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMA (US) 2002-01-23 EP disclosed
EP-1136479-A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2001-09-26 EP disclosed
US-5990155-A VIRICIDES AGAINST THE HIV-1 AND HIV-2 VIRUSES; REVERSE TRANSCRIPTASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-11-23 US disclosed
EP-0833826-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 1998-04-08 EP disclosed
US-5691372-A Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-11-25 US disclosed
WO-1996033187-A1 OXYGENATED-HETEROCYCLE CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1996-10-24 WO disclosed